Uncommon Oncogenic Drivers in NSCLC
By Karen L. Reckamp, MD, MS
Posted: March 1, 2019
Identification of genetic alterations in NSCLC has transformed diagnosis and treatment for patients with advanced disease....
Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung Cancer...
By Julien Mazieres, MD, PhD
Posted: October 2017
The standard of care for patients postresection for lung cancer is adjuvant chemotherapy, usually a platinum-based regimen.1 The...
Histologic Transformation From NSCLC to SCLC: A Mechanism of Resistance to Osimertinib and Other...
By Denis Moro-Sibilot, MD, MSc
Posted: April 16, 2020
EGFR tyrosine kinase inhibitors (TKIs) are the standard of care for mutated EGFR NSCLC. Today, one of...
Updated Results from the Phase III ALEX Trial: Embracing Hazard Ratios
By D. Ross Camidge, MD, and Mary W. Redman, PhD
Posted: August 2018
Updates of the primary analysis of the phase III ALEX trial were presented...
Lorlatinib in ROS1-Positive NSCLC: A Review of Recent Data
By Ben Solomon, MBBS, PhD, FRACP
Posted: August 19, 2020
ROS1 rearrangements are found in 1% to 2% of patients with NSCLC. They tend to occur...
ALK Testing in Europe
By Enriqueta Felip, MD, PhD
Posted: February 2018
ALK-directed TKIs are effective first- and second-line therapies in patients with ALK rearrangements. Testing of all patients with...
Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung Cancer...
By Cynthia L. Kryder, MS, CCC-Sp
Editor Note: IASLC Lung Cancer News is pleased to provide the following overview, which is followed by expert commentary...
Osimertinib: A New Option in Non-Small Cell Lung Cancer – Q&A with David R....
By Erik J. MacLaren, PhD
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), received FDA approval in November 2015 for use...
Alectinib and ALK-Positive Non-Small Cell Lung Cancer – Q&A with Alice T. Shaw, MD,...
By Erik J. MacLaren, PhD
Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that was recently approved in the US as a second- line...
Benefit of EGFR Mutation Analysis from Plasma Cell-Free DNA for Treatment of Advanced Non-Small...
By Tony S. K. Mok, BMSc, MD, FRCPC
Patients must first be identified as having an epidermal growth factor receptor (EGFR) mutation before they can...
